Actively Recruiting
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Led by Thomas Hope ยท Updated on 2026-04-03
199
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how Fluoroethyltyrosine (FET) Positron Emission Tomography (PET) scans can help detect and characterize brain tumors called intracranial neoplasms. The study focuses on distinguishing between treatment-related changes and tumor recurrence in patients with metastatic disease and gliomas, as well as differentiating between low-grade and high-grade gliomas. This observational study aims to improve understanding of tumor behavior and guide treatment decisions through imaging. Participants will receive a single FET PET scan lasting about 40 minutes after an injection of the FET drug given intravenously. Some adult participants may have up to two additional FET PET scans. The study includes two groups: one with patients who have previously been treated but have suspected recurrence, and another with patients who are about to undergo biopsy or surgery before standard treatment. Adverse events during the scans will be recorded. During the study, participants will undergo the FET PET imaging procedure in an outpatient setting. Researchers will assess tumor-to-background ratios and the accuracy of tumor detection by comparing scan results to pathology or imaging follow-up over up to three years. Safety and tolerability of the scans will be monitored. Participation involves imaging visits and follow-up for outcomes related to tumor detection and clinical status.
CONDITIONS
Brief Title
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Presence or suspicion of intracranial neoplasm in one of two groups: after primary treatment with suspicion of recurrence, or prior to treatment with planned biopsy or surgery
- Includes subgroups with recurrent metastatic lesions, recurrent high-grade gliomas (Grades 3 and 4), and recurrent low-grade gliomas (Grade 2)
- Age greater than 3 years
- Participation allowed even if enrolled in other clinical trials, including those using 5-aminolevulinic acid for surgery guidance
You will not qualify if you...
- Known incompatibility to PET, CT, or MRI scans
- Unlikely to comply with study procedures, restrictions, or requirements as judged by the Investigator
- Sedation or anesthesia may be used if participant cannot tolerate the exam
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single day with possible repeat scans
Participants undergo FET PET scan imaging to evaluate intracranial neoplasms and differentiate tumor types or recurrence.
1 to 3 imaging visits (outpatient)
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
L
Louise Magat
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here